CA
SNDX icon

Clearstead Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Clearstead Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219 Buy
+10
New +$208 ﹤0.01% 3183
2026
Q1 		– Sell
-35
Closed -$736 – 2782
2025
Q4 		$736 Sell
35
-53
-60% -$925 ﹤0.01% 2265
2025
Q3 		$1.35K Buy
+88
New +$1.15K ﹤0.01% 2558

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Clearstead Advisors's SNDX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 10 shares worth $219. The stake represents ﹤0.01% of the portfolio and ranks #3183 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in SNDX as recently as Q4 2025.

Clearstead Advisors first reported a position in SNDX in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.35K in Q3 2025. 68 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Clearstead Advisors held 10 shares of Syndax Pharmaceuticals worth $219 as of Q2 2026.
  • Syndax Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3183 holding.
  • Clearstead Advisors first reported a position in Syndax Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Clearstead Advisors's Syndax Pharmaceuticals position peaked at $1.35K in Q3 2025.
  • 68 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.